Antiepileptic Drugs (AED) Market to Expand at 4.4% CAGR from 2023 to 2030; UCB Acquired Zogenix to Enhance Product Portfolio

The global antiepileptic drugs (AED) market size stood at USD 15.55 billion in 2022. The market value is slated to rise from USD 16.50 billion in 2023 to USD 22.37 billion by 2030 at a CAGR of 4.4% during 2023-2030. Fortune Business Insights™ presents this information in its report titled “Antiepileptic Drugs (AED) Market Size, Share & COVID-19 Impact Analysis, By Drug Generation (First Generation, Second Generation, and Third Generation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2023-2030”.

Patients ailing from epilepsy exhibit loss of consciousness, severe emotional distress, and sudden changes in behavior. The market value is slated to surge with an increase in clinical trials and rising number of product approvals.

Disruptions in Clinical Trials Negatively Impacted Industry Expansion during COVID-19 Pandemic

The COVID-19 pandemic created disruptions in clinical trials, negatively affecting industry expansion. In 2020, leading players registered a drop in their revenues. However, the rising number of patient visits to neurological centers from 2022 onwards helped in the market recovery and is expected to propel the industry growth over the forecast period.

UCB Enters Three Collaborations to Study the Effect of Seizure Clusters on Patient and Caregiver Quality of Life

In August 2022, UCB announced plans to collaborate with three organizations. These constituted the Wisconsin Health Information Organization (WHIO), Le Bonheur Children’s Hospital, and Yale University. The partnerships were aimed at studying the impact of seizure clusters on the quality of life of patients and caregivers. The impact constitutes a less-studied area in the field of epilepsy research.

The WHIO partnership was aimed at understanding the clinical and economic impact of the under treatment of seizure clusters. It further intended to explore better outcome drivers. The project would examine healthcare utilization, prescribing trends, access barriers, costs, and disease prevalence by analyzing retrospective claims at a state level.  

Rising Government Investments to Impel Industry Expansion

Developing nations such as Brazil, China, and India record a higher prevalence rate of epilepsy. The governments in these countries are keen to provide active support and investments for enhancing the availability of various treatments. These steps are being undertaken for minimizing the burden of the disease in these countries. These factors are set to favor antiepileptic drugs market growth over the forecast period.

However, the industry expansion may be hindered due to issues associated with the supply of these drugs.

Companies Launch New Products to Strengthen Market Presence

Market players are keen to roll out new antiepileptic drugs for strengthening their presence in the industry. Companies are also focusing on R&D activities given the nearing of the patent expiration of key drugs. Pfizer is a leading player in the market on account of its global presence and a robust product portfolio.

Key Players

• Pfizer Inc. (U.S.)


• UCB S.A. (Belgium)


• GSK plc. (U.K.)


• H. Lundbeck A/S (Denmark)


• Eisai Co., Ltd. (Japan)


• Sanofi (France)


• Sunovion Pharmaceuticals Inc. (U.S.)


• Jazz Pharmaceuticals, Inc. (Ireland)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/antiepileptic-drug-market-101189

Key Industry Development

January 2022 – UCB acquired Zogenix for a value of USD 1.9 billion. The move formed part of its strategy to strengthen its epilepsy portfolio through the addition of Fintepla. The drug has been approved by the EMA and FDA for treating seizures associated with Dravet syndrome.

Further Report Findings

• North America AED market share dominates the global market driven by higher investments in R&D activities. Besides, the region exhibits an increased awareness regarding new treatment options among the patient population in the region.


• The Middle East & Africa and Latin America markets are set to grow owing to the development of healthcare infrastructure in these regions.


• Based on drug generation, the market is classified into first, second, and third generations. The second generation segment held a leading market share. This can be attributed to the seizure control potential of these drugs.


• By distribution channel, the market is segregated into online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies segment accounted for a prominent market share. This is due to the adequate number of reimbursement policies offered by these settings.

Table of Segmentation